Lupus Erythematosus: Cutaneous Manifestations and Treatment

Francisca Alves; Margarida Gonçalo

doi:10.29021/spdv.77.3.1118

Francisca Alves Interna de Dermatovenereologia, Serviço de Dermatologia, Centro Hospitalar de Coimbra, Coimbra, Portugal
Margarida Gonçalo Assistente Graduada de Dermatovenereologia, Serviço de Dermatologia, Centro Hospitalar de Coimbra, Coimbra, Portugal; Professora Convidada da Faculdade de Medicina da Universidade de Coimbra, Coimbra, Portugal

DOI: https://doi.org/10.29021/spdv.77.3.1118

Keywords: Lupus Erythematosus, Cutaneous/complications, Lupus Erythematosus, Cutaneous/diagnosis, Lupus Erythematosus, Cutaneous/therapy

Abstract

Cutaneous lupus erythematosus (CLE) includes a broad range of dermatologic manifestations, which may or may not be associated with systemic manifestations. Specific CLE - defined by the presence of an interface dermatitis on histopathological evaluation - is divided into several sub-types, namely acute CLE (ACLE), subacute CLE (SCLE) and chronic CLE (CCLE). CCLE includes discoid lupus erythematosus (DLE), as well as other rarer forms such as LE profundus (LEP). Nonspecific skin findings, such as livedo reticularis or purpura are more frequently seen in patients with systemic disease. Diagnosis requires classification of the subtype, through a combination of physical examination, laboratory studies, histology and sometimes direct immunofluorescence, at the same time ensuring to exclude systemic disease. Regarding the treatment of CLE, antimalarials and topical steroids continue to be the standard of care; however, immunosuppressants, thalidomide analogs and monoclonal antibodies are possible systemic therapies for recalcitrant disease. Patient education on proper sun protection and avoidance of triggers is crucial. This paper reviews the clinical manifestations of CLE, as well as the treatment.

Downloads

Download data is not yet available.

References

Rothfield N, Sontheimer RD, Bernstein M. Lupus erythematosus: systemic and cutaneous manifestations. Clin Dermatol. 2006;24:348–62.

Obermoser G, Sontheimer RD, Zelger B. Overview of common, rare and atypical manifestations of cutaneous lupus erythematosus and histopathological correlates. Lupus. 2010;19:1050–70. doi: 10.1177/0961203310370048.

Tebbe B, Orfanos CE. Epidemiology and socioeconomic impact of skin disease in lupus erythematosus. Lupus. 1997;6:96–104.

Durosaro O, Davis MDP, Reed KB, Rohlinger AL. Incidence of cutaneous lupus erythematosus, 1965-2005: a population-based study. Arch Dermatol. 2009;145:249–53. doi: 10.1001/archdermatol.2009.21.

Gronhagen CM, Fored CM, Granath F, Nyberg F. Cutaneous lupus erythematosus and the association with systemic lupus erythematosus: a population- based cohort of 1088 patients in Sweden. Br J Dermatol. 2011 ;164:1335–41. doi: 10.1111/j.1365--2133.2011.10272.x.

Jarukitsopa S, Hoganson DD, Crowson CS, Sokumbi O, Davis MD, Michet Jr. CJ, et al. Epidemiology of systemic lupus erythematosus and cutaneous lupus erythematosus in a predominantly white population in the United States. Arthritis Care Res. 2015;67:817–28. doi: 10.1002/acr.22502.

Jimenez S, Cervera R, Font J, Ingelmo M. The epidemiology of systemic lupus erythematosus. Clin Rev Allergy Immunol. 2003;25:3–12.

Chiu Y-M, Lai C-H. Nationwide population-based epidemiologic study of systemic lupus erythematosus in Taiwan. Lupus. 2010;19:1250–5. doi: 10.1177/0961203310373780.

Gilliam JN, Sontheimer RD. Distinctive cutaneous subsets in the spectrum of lupus erythematosus. J Am Acad Dermatol. 1981;4:471–5.

Callen JP. Cutaneous lupus erythematosus: Reflecting on practice-changing observations over the past 50 years. Clin Dermatol. 2018;36:442–9. doi: 10.1016/j.clindermatol.2018.04.002.

Kuhn A, Landmann A. The classification and diagnosis of cutaneous lupus erythematosus. J Autoimmun. 2014;49:14–9. doi: 10.1016/j.jaut.2014.01.021.

Chen KL, Krain RL, Werth VP. Advancing understanding, diagnosis, and therapies for cutaneous lupus erythematosus within the broader context of systemic lupus erythematosus. F1000Res. 2019;8:1–7. doi: 10.12688/f1000research.17787.1.

Grönhagen CM, Nyberg F. Cutaneous lupus erythematosus: An update. Indian Dermatol Online J. 2014;5:7–13.

Kuhn A, Wenzel J, Bijl M. Lupus erythematosus revisited. Semin Immunopathol. 2016;38:97–112.

Ng PPL, Tan SH, Koh ET, Tan T. Epidemiology of cutaneous lupus erythematosus in a tertiary referral centre in Singapore. Australas J Dermatol. 2000;41:229–33. doi:10.1046/j.1440-0960.2000.00443.x

Fabbri P, Cardinali C, Giomi B, Caproni M. Cutaneous lupus erythematosus. Am J Clin Dermatol. 2003;4:449–65. doi:10.2165/00128071-200304070-00002

Chiewchengchol D, Murphy R, Edwards SW, Beresford MW. Mucocutaneous manifestations in juvenile-onset systemic lupus erythematosus : a review of literature. 2015;13:1–9.

Walling HW, Sontheimer RD. Cutaneous Lupus Erythematosus. Am J Clin Dermatol. 2009;10:365–81. doi:0.2165/11310780-000000000-00000

Mascarenhas R, Tellechea O, Oliveira H, Reis J, Cordeiro M, Migueis J. Nasal septum perforation as the presenting sign of lupus erythematosus. Dermatol Online J. 2005;11:12.

Okon LG, Werth VP. Cutaneous lupus erythematosus: Diagnosis and treatment. Best Pract Res Clin Rheumatol. 2013;27:391-404. doi: 10.1016/j.berh.2013.07.008.

Tebbe B, Mansmann U, Wollina U, Auer-Grumbach P, Licht-Mbalyohere A, Arensmeier M, et al. Markers in cutaneous lupus erythematosus indicating systemic involvement. A multicenter study on 296 patients. Acta Derm Venereol. 1997;77:305–8.

Sontheimer RD, Maddison PJ, Reichlin M, Jordon RE, Stastny P, Gilliam JN. Serologic and HLA Associations in Subacute Cutaneous Lupus Erythematosus, a Clinical Subset of Lupus Erythematosus. Ann Intern Med. 1982;97:664–71. doi:10.7326/0003-4819-97-5-664

Black DR, Hornung CA, Schneider PD, Callen JP. Frequency and severity of systemic disease in patients with subacute cutaneous lupus erythematosus. Arch Dermatol. 2002;138:1175–8.

Cohen MR, Crosby D. Systemic disease in subacute cutaneous lupus erythematosus: a controlled comparison with systemic lupus erythematosus. J Rheumatol. 1994;21:1665–9.

Sontheimer RD. Subacute cutaneous lupus erythematosus. Clin Dermatol. 1985;3:58–68.

Parodi A, Caproni M, Cardinali C, Bernacchi E, Fuligni A, De Panfilis G, et al. Clinical, Histological and Immunopathological Features of 58 Patients with Subacute Cutaneous Lupus erythematosus. Dermatology. 2000;200:6–10. doi: 10.1159/000018307

Moghadam-Kia S, Chilek K, Gaines E, Costner M, Rose ME, Okawa J, et al. Cross-sectional analysis of a collaborative Web-based database for lupus erythematosus-associated skin lesions: prospective enrollment of 114 patients. Arch Dermatol. 2009;145:255–60.

Sontheimer RD, Thomas JR, Gilliam JN. Subacute Cutaneous Lupus Erythematosus: A Cutaneous Marker for a Distinct Lupus Erythematosus Subset. Arch Dermatol. 1979;115:1409–15.

Caproni M, Cardinali C, Salvatore E, Fabbri P. Subacute cutaneous lupus erythematosus with pityriasis-like cutaneous manifestations. Int J Dermatol. 2001;40:59–62. doi: 10.1046/j.1365-4362.2001.01067-5.x

Kuhn A, Sticherling M, Bonsmann G. Clinical manifestations of cutaneous lupus erythematosus. J Dtsch Dermatol Ges. 2007;5:1124–37.

Nieboer C, Tak-Diamand Z, Van Leeuwen-Wallau HE. Dust-like particles: a specific direct immunofluorescence pattern in sub-acute cutaneous lupus erythematosus. Br J Dermatol. 1988;118:725–9.

Biazar C, Sigges J, Patsinakidis N, Ruland V, Amler S, Bonsmann G, et al. Cutaneous lupus erythematosus: First multicenter database analysis of 1002 patients from the European Society of Cutaneous Lupus Erythematosus (EUSCLE). Autoimmun Rev. 2013;12:444–54.

Chong BF, Song J, Olsen NJ. Determining risk factors for developing systemic lupus erythematosus in patients with discoid lupus erythematosus. Br J Dermatol. 2012;166:29–35.

Vera-Recabarren MA, García-Carrasco M, Ramos-Casals M, Herrero C. Comparative analysis of subacute cutaneous lupus erythematosus and chronic cutaneous lupus erythematosus: clinical and immunological study of 270 patients. Br J Dermatol. 2010;162:91–101. doi: 10.1111/j.1365-2133.2009.09472.x.

Boeckler P, Milea M, Meyer A, Uring-Lambert B, Heid E, Hauptmann G, et al. The combination of complement deficiency and cigarette smoking as risk factor for cutaneous lupus erythematosus in men; a focus on combined C2/C4 deficiency. Br J Dermatol. 2005;152:265–70. doi: 0.1111/j.1365-2133.2004.06308.x

McCauliffe DP. Cutaneous lupus erythematosus. Semin Cutan Med Surg. 2001;20:14–26.

Magro CM, Crowson AN, Harrist TJ. Atypical lymphoid infiltrates arising in cutaneous lesions of connective tissuedisease. Am J Dermatopathol. 1997;19:446-55.

Hedrich CM, Fiebig B, Hauck FH, Sallmann S, Hahn G,Pfeiffer C, et al. Chilblain lupus erythematosus–a reviewof literature. Clin Rheumatol. 2008;27:949–54.doi:10.1007/s10067-008-0942-9

Tungler V, Silver RM, Walkenhorst H, Gunther C, Lee-Kirsch MA. Inherited or de novo mutation affectingaspartate 18 of TREX1 results in either familialchilblain lupus or Aicardi-Goutieres syndrome. Br JDermatol. 2012;167:212-4. doi: 10.1111/j.1365-2133.2012.10813.x.

Kuhn A, Richter-Hintz D, Oslislo C, Ruzicka T, MegahedM, Lehmann P. Lupus erythematosus tumidus--a neglectedsubset of cutaneous Lupus erythematosus: report of 40 cases. Arch Dermatol. 2000;136:1033–41.

Schmitt V, M Meuth A, Amler S, Kuehn E, Haust M, MesserG, et al. Lupus erythematosus tumidus is a separatesubtype of cutaneous lupus erythematosus. Br JDermatol. 2010;163:230; author reply 231-2. doi:10.1111/j.1365-2133.2010.09795.x.

Kuhn A, Bein D, Bonsmann G. The 100th anniversaryof lupus erythematosus tumidus. Autoimmun Rev.2009;8:441–8.

Romero LS, Bari O, Smith C, Schneider J, Cohen P. Toxicepidermal necrolysis-like acute cutaneous lupus erythematosus:report of a case and review of the literaturePermalink. Dermatol Online J. 2018;24.

Yildirim Cetin G, Sayar H, Ozkan F, Kurtulus S, Kesici F,Sayarlioglu M. A case of toxic epidermal necrolysis-likeskin lesions with systemic lupus erythematosus and reviewof the literature. Lupus. 2018;22:839–46. doi:10.1177/0961203313492242.

Chanprapaph K, Sawatwarakul S, Vachiramon V. A12-year retrospective review of bullous systemic lupuserythematosus in cutaneous and systemic lupus erythematosuspatients. Lupus. 2017;26:1278–84. doi:10.1177/0961203317699714.

Pons-Estel G, Quintana R, Alarcón G, Sacnún M, UgarteGil M, Pons-Estel B. A 12-year retrospective reviewof bullous systemic lupus erythematosus in cutaneousand systemic lupus erythematosus patients. Lupus.2018;27:1753–4. doi: 10.1177/0961203318776104.

Cardinali C, Caproni M, Bernacchi E, Amato L, FabbriP. The spectrum of cutaneous manifestations inlupus erythematosus--the Italian experience. Lupus.2000;9:417–23.

Cutolo M, Melsens K, Wijnant S, Ingegnoli F, ThevissenK, De Keyser F, et al. Nailfold capillaroscopy in systemiclupus erythematosus: A systematic review and criticalappraisal. Autoimmun Rev. 2018;17:344–52.

Concha J, Werth VP. Alopecias in lupus erythematosus.Lupus Sci Med. 2018;5:e000291.

Lipsker D, Saurat J-H. Neutrophilic cutaneous lupuserythematosus. Dermatology. 2008;216:283–6. doi:10.1159/000113940

Gusdorf L, Bessis D, Lipsker D. Lupus erythematosus andneutrophilic urticarial dermatosis: a retrospective studyof 7 patients. Medicine. 2014 ;93:e351.

Mitsias DI, Kapsogeorgou EK, Moutsopoulos HM.Sjögren’s syndrome: why autoimmune epithelitis?Oral Dis. 2006;12:523–32. doi: 10.1111/j.1601-0825.2006.01292.x

Marin GG, Cardiel MH, Cornejo H, Viveros ME. Prevalenceof antinuclear antibodies in 3 groups of healthyindividuals: blood donors, hospital personnel,and relatives of patients with autoimmune diseases.J Clin Rheumatol. 2009;15:325-9. doi: 10.1097/RHU.0b013e3181bb971b.

Sticherling M, Bonsmann G, Kuhn A. Diagnostic approachand treatment of cutaneous lupus erythematosus.J Dtsch Dermatol Ges. 2008;6:48–59. doi:10.1111/j.1610-0387.2007.06557.x

Weyd H, Abeler-Dörner L, Linke B, Mahr A, JahndelV, Pfrang S, et al. Annexin A1 on the Surface of EarlyApoptotic Cells Suppresses CD8+ T Cell Immunity.PLoS One. 2013 30;8:e62449. doi:10.1371/journal.pone.0062449

Kretz CC, Norpo M, Abeler-Dörner L, Linke B, Haust M,Edler L, et al. Anti-annexin 1 antibodies: A new diagnosticmarker in the serum of patients with discoidlupus erythematosus. Exp Dermatol. 2010;19:919–21.doi:10.1111/j.1600-0625.2010.01145.x

David-Bajar KM, Bennion SD, DeSpain JD, Golitz LE, LeeLA. Clinical, Histologic, and Immunofluorescent DistinctionsBetween Subacute Cutaneous Lupus Erythematosusand Discoid Lupus Erythematosus. J Invest Dermatol.1992;99:251–7.

Kuhn A, Wozniacka A, Szepietowski JC, Gläser R, LehmannP, Haust M, et al. Photoprovocation in CutaneousLupus Erythematosus: A Multicenter StudyEvaluating a Standardized Protocol. J Invest Dermatol.2011;131:1622–30. doi:10.1038/jid.2011.101

Aringer M, Costenbader K, Daikh D, Brinks R, MoscaM, Ramsey-goldman R, et al. 2019 European LeagueAgainst Rheumatism / American College of RheumatologyClassification Criteria for Systemic Lupus Erythematosus.Arthritis Rheumatol. 2019;71:1400-12. doi:10.1002/art.40930

Kuhn A, Sonntag M, Richter-Hintz D, Oslislo C, MegahedM, Ruzicka T, et al. Phototesting in lupus erythematosus:A 15-year experience. J Am Acad Dermatol.2001;45:86–95.

Kuhn A, Gensch K, Haust M, Meuth A-M, Boyer F, DupuyP, et al. Photoprotective effects of a broad-spectrum sunscreenin ultraviolet-induced cutaneous lupus erythematosus:A randomized, vehicle-controlled, double-blindstudy. J Am Acad Dermatol. 2011;64:37–48.

Ezra N, Jorizzo J. Hydroxychloroquine and smoking inpatients with cutaneous lupus erythematosus. Clin ExpDermatol. 2012;37:327–34. doi:10.1111/j.13652230.2011.04266.x

Piette EW, Foering KP, Chang AY, Okawa J, Ten HaveTR, Feng R, et al. Impact of smoking in cutaneous lupuserythematosus. Arch Dermatol. 2012 ;148:317–22.

Ortiz A, Grando SA. Smoking and the skin. Int JDermatol. 2012;51:250–62. doi:10.1111/j.13654632.2011.05205.x

Sárdy M, Ruzicka T, Kuhn A. Topical calcineurin inhibitorsin cutaneous lupus erythematosus. Arch DermatolRes. 2008;301:93. doi:10.1007/s00403-008-0894-6

Chang AY, Werth VP. Treatment of Cutaneous Lupus.Curr Rheumatol Rep. 2011;13:300–7. doi:10.1007/s11926-011-0180-z

Kuhn A, Gensch K, Haust M, Schneider SW, BonsmannG, Gaebelein-Wissing N, et al. Efficacy of tacrolimus0.1% ointment in cutaneous lupus erythematosus: amulticenter, randomized, double-blind, vehicle-controlledtrial. J Am Acad Dermatol. 2011;65:54–64,64.e1-2.

Tzung T-Y, Liu Y-S, Chang H-W. Tacrolimus vs. clobetasolpropionate in the treatment of facial cutaneous lupuserythematosus: a randomized, double-blind, bilateralcomparison study. Br J Dermatol. 2007;156:191–2.doi:10.1111/j.1365-2133.2006.07595.x

Erceg A, Bovenschen HJ, van de Kerkhof PCM, de JongEMJG, Seyger MMB. Efficacy and safety of pulsed dyelaser treatment for cutaneous discoid lupus erythematosus.J Am Acad Dermatol. 2009;60:626–32.

Chang AY, Piette EW, Foering KP, Tenhave TR, OkawaJ, Werth VP. Response to antimalarial agents in cutaneouslupus erythematosus: a prospective analysis. ArchDermatol. 2011;147:1261–7.

Patel P, Werth V. Cutaneous lupus erythematosus: a review.Dermatol Clin. 2002;20:373–85, v.

Marmor MF, Kellner U, Lai TYY, Melles RB, Mieler WF.Recommendations on Screening for Chloroquine andHydroxychloroquine Retinopathy (2016 Revision).Ophthalmology. 2016;123:1386–94.

Winkelmann RR, Kim GK, Del Rosso JQ. Treatment ofCutaneous Lupus Erythematosus: Review and Assessmentof Treatment Benefits Based on Oxford Centre forEvidence-based Medicine Criteria. J Clin Aesthet Dermatol.2013;6:27–38.

Kuhn A, Ruland V, Bonsmann G. Cutaneous lupuserythematosus: Update of therapeutic options: Part I. JAm Acad Dermatol. 2011;65:e179–93. doi: 10.1016/j.jaad.2010.06.018

Wenzel J, Brähler S, Bauer R, Bieber T, Tüting T. Efficacyand safety of methotrexate in recalcitrant cutaneouslupus erythematosus: results of a retrospective study in43 patients. Br J Dermatol. 2005;153:157–62. doi:10.1111/j.1365-2133.2005.06552.x

Al-Mutairi N, Rijhwani M, Nour-Eldin O. HypertrophicLupus Erythematosus Treated Successfully with Acitretinas Monotherapy. J Dermatol. 2005;32:482–6.doi:10.1111/j.1346-8138.2005.tb00785.x

Ruzicka T, Goerz G. Dapsone in the treatment of lupuserythematosus. Br J Dermatol. 1981;104:53–7.

Hall RP, Lawley TJ, Smith HR, Katz SI. Bullous eruptionof systemic lupus erythematosus. Dramatic response todapsone therapy. Ann Intern Med. 1982 ;97:165–70.

Kreuter A, Tomi NS, Weiner SM, Huger M, Altmeyer P,Gambichler T. Mycophenolate sodium for subacute cutaneouslupus erythematosus resistant to standard therapy.Br J Dermatol. 2007;156:1321–7. doi:10.1111/j.13652133.2007.07826.x

Ashinoff R, Werth VP, Franks AG. Resistant discoidlupus erythematosus of palms and soles: Successfultreatment with azathioprine. J Am Acad Dermatol.1988;19:961–5.

Tsokos GC, Caughman SW, Klippel JH. SuccessfulTreatment of Generalized Discoid Skin Lesions WithAzathioprine: Its Use in a Patient With Systemic LupusErythematosus. Arch Dermatol. 1985;121:1323–5.

Shehade S. Successful Treatment of Generalized DiscoidSkin Lesions With Azathioprine. Arch Dermatol.1986;122:376–7.

Hasper MF. Chronic cutaneous lupus erythematosus:thalidomide treatment of 11 patients. Arch Dermatol.1983;119:812–5.

Knop J, Bonsmann G, Happle R, Ludolph A, Matz DR,Mifsud EJ, et al. Thalidomide in the treatment of sixtycases of chronic discoid lupus erythematosus. Br J Dermatol.1983;108:461–6.

Braunstein I, Goodman NG, Rosenbach M, OkawaJ, Shah A, Krathen M, et al. Lenalidomide therapy intreatment-refractory cutaneous lupus erythematosus:Histologic and circulating leukocyte profile and potentialrisk of a systemic lupus flare. J Am Acad Dermatol.2012;66:571–82.

Cortés-Hernández J, Ávila G, Vilardell-Tarrés M, Ordi-Ros J. Efficacy and safety of lenalidomide for refractorycutaneous lupus erythematosus. Arthritis Res Ther.2012;14:R265. doi:10.1186/ar4111

Shah A, Albrecht J, Bonilla-Martinez Z, Okawa J, RoseM, Rosenbach M, et al. Lenalidomide for the treatmentof resistant discoid lupus erythematosus. Arch Dermatol.2009;14:303–6.

Fennira F, Chasset F, Soubrier M, Cordel N, Petit A,Francès C. Lenalidomide for refractory chronic and subacutecutaneous lupus erythematosus: 16 patients. JAm Acad Dermatol. 2016;74:1248–51. doi:10.1016/j.jaad.2016.01.054

Baret I, De Haes P. Thalidomide: Still an important secondline treatment in refractory cutaneous lupus erythematosus?J Dermatolog Treat. 2015;26:173–7. doi:0.3109/09546634.2014.906036

Cortés-Hernández J, Torres-Salido M, Castro-MarreroJ, Vilardell-Tarres M, Ordi-Ros J. Thalidomidein the treatment of refractory cutaneous lupus erythematosus:prognostic factors of clinical outcome. Br JDermatol. 2012;166:616–23. doi:10.1111/j.13652133.2011.10693.x

Bastuji-Garin S, Ochonisky S, Bouche P, Gherardi RK,Duguet C, Djerradine Z, et al. Incidence and Risk Factorsfor Thalidomide Neuropathy: a Prospective Studyof 135 Dermatologic Patients. J Invest Dermatol.2002;119:1020–6.

Vital EM, Wittmann M, Edward S, Md Yusof MY, MacIverH, Pease CT, et al. Brief report: responses to rituximabsuggest B cell-independent inflammation in cutaneoussystemic lupus erythematosus. Arthritis Rheumatol. 2015;67:1586–91.

Vashisht P, Borghoff K, O’Dell JR, Hearth-Holmes M.Belimumab for the treatment of recalcitrant cutaneouslupus. Lupus. 2017;26:857–64.